Novartis Investigative Site

Tokushima 770-8503

0 studies enrolling now · 1 studies all time

What they study most

Sporadic Inclusion Body Myositis

Studies at this site

• An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 — Completed